<?xml version='1.0' encoding='utf-8'?>
<document id="23324515"><sentence text="Inadequate therapeutic response to a recommended antituberculosis fixed-dose combination regimen in an overweight patient with Mycobacterium bovis infection." /><sentence text="To report a case of an overweight man with lymph node tuberculosis due to Mycobacterium bovis, a part of the Mycobacterium tuberculosis complex, treated with fixed-dose combination (FDC) chemotherapy" /><sentence text="" /><sentence text="Following guidelines, according to the patient's weight (92 kg), we prescribed the maximum recommended doses of isoniazid-rifampin-pyrazinamide FDC" /><sentence text=" It led initially to underdosing, with a poor clinical outcome, justifying increased doses and a complex regimen using separate drugs (isoniazid 600 mg, rifampin 1200 mg, and levofloxacin 1000 mg) to achieve therapeutic drug concentrations and clinical response"><entity charOffset="135-144" id="DDI-PubMed.23324515.s5.e0" text="isoniazid" /><entity charOffset="153-161" id="DDI-PubMed.23324515.s5.e1" text="rifampin" /><entity charOffset="175-187" id="DDI-PubMed.23324515.s5.e2" text="levofloxacin" /><pair ddi="false" e1="DDI-PubMed.23324515.s5.e0" e2="DDI-PubMed.23324515.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23324515.s5.e0" e2="DDI-PubMed.23324515.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23324515.s5.e0" e2="DDI-PubMed.23324515.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23324515.s5.e1" e2="DDI-PubMed.23324515.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23324515.s5.e1" e2="DDI-PubMed.23324515.s5.e2" /></sentence><sentence text="" /><sentence text="Usually recommended doses of FDC chemotherapies may be inappropriate in overweight patients" /><sentence text=" We discuss here the different factors that may be involved in poor clinical outcomes, particularly the consequences of excess weight on drug metabolism: drug-drug interaction, FDC use, generic formulation use, intestinal malabsorption, and acetylation profile" /><sentence text="" /><sentence text="Therapeutic drug monitoring in overweight patients may be useful in the clinical setting to help clinicians individualize drug therapeutic regimens and optimize drug response, adherence, and safety" /><sentence text="" /></document>